Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Treatment of anthrax

INTRODUCTION

The incidence of anthrax in humans has decreased during the past century, and it is now very rare in developed countries including the United States. From 1980 through 2000, only seven cases of anthrax were reported to the United States Centers for Disease Control and Prevention (CDC) [1]. However, in 2001, 22 confirmed or suspected anthrax cases occurred in the United States after Bacillus anthracis spores were sent through the mail in powder-containing envelopes [2].

Sporadic cases of inhalation and cutaneous anthrax also occurred between 2006 and 2008 in persons using contaminated imported animal hides for drum making, including two cases of cutaneous anthrax in the United States in a drum maker and a family member [3,4]. Both cutaneous and inhalation anthrax have also been associated with the playing of goatskin drums contaminated with Bacillus anthracis spores [5-7]. (See "Microbiology, pathogenesis, and epidemiology of anthrax", section on 'Bioterrorism' and "Microbiology, pathogenesis, and epidemiology of anthrax", section on 'Natural infection'.)

Spores can persist in the soil for years to decades. Decontamination of the soil is generally not practical; thus, sporadic cases of epizootic anthrax continue to occur in areas of high endemicity, such as Iran, Iraq, Turkey, Pakistan, and sub-Saharan Africa, where the use of anthrax vaccine in animals is not comprehensive. Animals become infected with B. anthracis by ingesting spores while grazing on contaminated grass or feed. Naturally-occurring transmission to humans occurs through direct exposure to infected animals or animal products through skin exposure, ingestion, or inhalation. (See "Microbiology, pathogenesis, and epidemiology of anthrax", section on 'Natural infection'.)

The treatment of anthrax will be reviewed here. The pathogenesis, epidemiology, clinical manifestations, diagnosis, and prevention of anthrax are discussed separately. (See "Microbiology, pathogenesis, and epidemiology of anthrax" and "Clinical manifestations and diagnosis of anthrax" and "Prevention of anthrax".)

TREATMENT

B. anthracis is highly susceptible to a variety of antimicrobial agents including penicillin, chloramphenicol, tetracycline, erythromycin, streptomycin, and fluoroquinolones [3-5]. B. anthracis is NOT susceptible to cephalosporins or trimethoprim-sulfamethoxazole [3-7]; thus, these agents should not be used for the treatment or prevention of anthrax.

                

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jul 2014. | This topic last updated: Sep 26, 2013.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Hopkins RS, Jajosky RA, Hall PA, et al. Summary of notifiable diseases--United States, 2003. MMWR Morb Mortal Wkly Rep 2005; 52:1.
  2. Jernigan DB, Raghunathan PL, Bell BP, et al. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 2002; 8:1019.
  3. Lightfoot N, Scott R, Turnbull B. Antimicrobial susceptibility of Bacillus anthracis. Salisbury Med Bull Suppl 1990; 68:95.
  4. Doğanay M, Aydin N. Antimicrobial susceptibility of Bacillus anthracis. Scand J Infect Dis 1991; 23:333.
  5. Turnbull PC, Sirianni NM, LeBron CI, et al. MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest. J Clin Microbiol 2004; 42:3626.
  6. Luna VA, King DS, Gulledge J, et al. Susceptibility of Bacillus anthracis, Bacillus cereus, Bacillus mycoides, Bacillus pseudomycoides and Bacillus thuringiensis to 24 antimicrobials using Sensititre automated microbroth dilution and Etest agar gradient diffusion methods. J Antimicrob Chemother 2007; 60:555.
  7. Bakici MZ, Elaldi N, Bakir M, et al. Antimicrobial susceptibility of Bacillus anthracis in an endemic area. Scand J Infect Dis 2002; 34:564.
  8. Centers for Disease Control and Prevention (CDC). Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep 2001; 50:909.
  9. Quinn C, Turnbull P. Anthrax. In: Topley and Wilson's Microbiology and Microbial Infection, 9th ed, Hausler WJ, Sussman M (Eds), Edward Arnold, London 1998. p.799.
  10. Pile JC, Malone JD, Eitzen EM, Friedlander AM. Anthrax as a potential biological warfare agent. Arch Intern Med 1998; 158:429.
  11. Ronaghy HA, Azadeh B, Kohout E, Dutz W. Penicillin therapy of human cutaneous anthrax. Curr Ther Res Clin Exp 1972; 14:721.
  12. Dixon TC, Meselson M, Guillemin J, Hanna PC. Anthrax. N Engl J Med 1999; 341:815.
  13. Centers for Disease Control and Prevention (CDC). Human anthrax associated with an epizootic among livestock--North Dakota, 2000. MMWR Morb Mortal Wkly Rep 2001; 50:677.
  14. Bartlett JG, Inglesby TV Jr, Borio L. Management of anthrax. Clin Infect Dis 2002; 35:851.
  15. Stern EJ, Uhde KB, Shadomy SV, et al. Conference report on public health and clinical guidelines for anthrax [conference summary]. Emerg Infect Dis [serial on the Internet] 2008; 14. http://www.cdc.gov/EID/content/14/4/07-0969.htm (Accessed on February 11, 2008).
  16. Centers for Disease Control and Prevention (CDC). Update: Interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax. MMWR Morb Mortal Wkly Rep 2001; 50:1014.
  17. Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997; 278:399.
  18. ACOG Committee on Obstetric Practice. ACOG Committee Opinion number 268, February 2002. Management of asymptomatic pregnant or lactating women exposed to anthrax. American College of Obstetricians and Gynecologists. Obstet Gynecol 2002; 99:366.
  19. Centers for Disease Control and Prevention (CDC). Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis. MMWR Morb Mortal Wkly Rep 2001; 50:960.
  20. U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Commentary on non-labeled dosing of oral amoxicillin in adults and pediatrics for post-exposure inhalational anthrax http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm072106.htm (Accessed on February 12, 2009).
  21. Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994; 266:1202.
  22. Food and Drug Administration. Prescription Drug Products: Doxycycline and penicillin G procaine administration for inhalational anthrax (post-exposure). In: Federal Register, November 2, 2001.
  23. Nathan RV, Rhew DC, Murray C, et al. In-hospital observation after antibiotic switch in pneumonia: a national evaluation. Am J Med 2006; 119:512.e1.
  24. Holty JE, Bravata DM, Liu H, et al. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 2006; 144:270.
  25. Brachman PS. Inhalation anthrax. Ann N Y Acad Sci 1980; 353:83.
  26. Sejvar JJ, Tenover FC, Stephens DS. Management of anthrax meningitis. Lancet Infect Dis 2005; 5:287.
  27. Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001; 7:933.
  28. Walsh JJ, Pesik N, Quinn CP, et al. A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. Clin Infect Dis 2007; 44:968.
  29. Kanafani ZA, Ghossain A, Sharara AI, et al. Endemic gastrointestinal anthrax in 1960s Lebanon: clinical manifestations and surgical findings. Emerg Infect Dis 2003; 9:520.
  30. Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A 1993; 90:2291.
  31. Lanska DJ. Anthrax meningoencephalitis. Neurology 2002; 59:327.
  32. Doust JY, Sarkarzadeh A, Kavoossi K. Corticosteroid in treatment of malignant edema of chest wall and neck (anthrax). Dis Chest 1968; 53:773.
  33. Artenstein AW, Opal SM. Novel approaches to the treatment of systemic anthrax. Clin Infect Dis 2012; 54:1148.
  34. Lucchesi, PF. Serum treatment of 19 cases of anthrax including one of external, internal and bacteremic type. Am J Med Sci 1932; 183:795.
  35. Lucchesi, PF, Gildersleeve, N. The treatment of anthrax. JAMA 1941; 116:1506.
  36. Knudson GB. Treatment of anthrax in man: history and current concepts. Mil Med 1986; 151:71.
  37. Migone TS, Subramanian GM, Zhong J, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 2009; 361:135.
  38. Barochia AV, Cui X, Sun J, et al. Protective antigen antibody augments hemodynamic support in anthrax lethal toxin shock in canines. J Infect Dis 2012; 205:818.
  39. US Food and Drug Administration. FDA News Release. FDA approves raxibacumab to treat inhalational anthrax. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332341.htm (Accessed on January 02, 2013).
  40. Anti-Infective Drugs Advisory Committee Meeting - 02 November 2012. Human Genome Sciences, Inc. Briefing Document, Raxibacumab - Treatment of Inhalational Anthrax. BLA 125349. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM326185.pdf (Accessed on January 03, 2013).
  41. Raxibacumab prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125349s000lbl.pdf (Accessed on January 03, 2013).
  42. Nabel GJ. Protecting against future shock--inhalational anthrax. N Engl J Med 2009; 361:191.
  43. Anaraki S, Addiman S, Nixon G, et al. Investigations and control measures following a case of inhalation anthrax in East London in a drum maker and drummer, October 2008. Euro Surveill 2008; 13.